ENSYSCE BIOSCIENCES INC (ENSC) Stock News

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

12 Health Care Stocks Moving In Friday's After-Market Session

Mentions: DRRX SSII RAPT HCTI ...

Ensysce Biosciences Reports First Quarter 2025 Financial Results

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

12 Health Care Stocks Moving In Thursday's Intraday Session

Mentions: CYH JAGX BSGM INTS ...

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled

The company stated that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.

Mentions: VXF GM

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

/PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ: ENSC) CEO Dr. Lynn Kirkpatrick and Dr....